Paroxetine pharmacokinetics in depressed children and adolescents

Robert L Findling, Michael D. Reed, Carolyn Myers, Mary Ann O'Riordan, Sandra Fiala, Lisa Branicky, Byron Waldorf, Jeffrey L. Blumer

Research output: Contribution to journalArticle

Abstract

Objective: To describe the pharmacokinetics and safety of paroxetine in children and adolescents and to explore the role of genetic polymorphisms in paroxetine pharmacokinetics. Method: Thirty depressed youths were enrolled. Samples for phenotyping with respect to cytochrome P450 2D6 (CYP2D6) and catechol-O-methyltransferase were collected. A single 10-mg dose of paroxetine was then administered followed by 5 days of blood and urine collection for pharmacokinetic analyses. Subjects subsequently received open treatment for 8 weeks, and weekly blood samples were obtained for plasma concentration measurements. Results: There was tremendous interindividual variability in paroxetine disposition. The mean half-life of paroxetine was 11.1 ± 5.2 (SD) hours. The average clearance was 88.7 ± 66.4 mL/min/kg. The mean area under the plasma drug concentration curve was 0.09 ± 0.10 μg/mL·hr. Within-subject variability of plasma paroxetine concentrations was generally not significant. Clearance and fractional urinary excretion of paroxetine were found to correlate with CYP2D6 activity. Two subjects developed hypomania necessitating drug discontinuation. No clinically significant changes in any safety assessments were noted. Conclusions: Paroxetine is more rapidly cleared in youths than adults and may be given once daily in this population. Short-term treatment with paroxetine appears safe and well tolerated in this relatively small sample of pediatric patients.

Original languageEnglish (US)
Pages (from-to)952-959
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume38
Issue number8
StatePublished - 1999
Externally publishedYes

Fingerprint

Paroxetine
Pharmacokinetics
Cytochrome P-450 CYP2D6
Safety
Catechol O-Methyltransferase
Urine Specimen Collection
Genetic Polymorphisms
Pharmaceutical Preparations
Half-Life
Pediatrics

Keywords

  • Depression
  • Paroxetine
  • Pharmacokinetics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Findling, R. L., Reed, M. D., Myers, C., O'Riordan, M. A., Fiala, S., Branicky, L., ... Blumer, J. L. (1999). Paroxetine pharmacokinetics in depressed children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38(8), 952-959.

Paroxetine pharmacokinetics in depressed children and adolescents. / Findling, Robert L; Reed, Michael D.; Myers, Carolyn; O'Riordan, Mary Ann; Fiala, Sandra; Branicky, Lisa; Waldorf, Byron; Blumer, Jeffrey L.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 38, No. 8, 1999, p. 952-959.

Research output: Contribution to journalArticle

Findling, RL, Reed, MD, Myers, C, O'Riordan, MA, Fiala, S, Branicky, L, Waldorf, B & Blumer, JL 1999, 'Paroxetine pharmacokinetics in depressed children and adolescents', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 38, no. 8, pp. 952-959.
Findling, Robert L ; Reed, Michael D. ; Myers, Carolyn ; O'Riordan, Mary Ann ; Fiala, Sandra ; Branicky, Lisa ; Waldorf, Byron ; Blumer, Jeffrey L. / Paroxetine pharmacokinetics in depressed children and adolescents. In: Journal of the American Academy of Child and Adolescent Psychiatry. 1999 ; Vol. 38, No. 8. pp. 952-959.
@article{7c488d05c8474f51808d5df39666298d,
title = "Paroxetine pharmacokinetics in depressed children and adolescents",
abstract = "Objective: To describe the pharmacokinetics and safety of paroxetine in children and adolescents and to explore the role of genetic polymorphisms in paroxetine pharmacokinetics. Method: Thirty depressed youths were enrolled. Samples for phenotyping with respect to cytochrome P450 2D6 (CYP2D6) and catechol-O-methyltransferase were collected. A single 10-mg dose of paroxetine was then administered followed by 5 days of blood and urine collection for pharmacokinetic analyses. Subjects subsequently received open treatment for 8 weeks, and weekly blood samples were obtained for plasma concentration measurements. Results: There was tremendous interindividual variability in paroxetine disposition. The mean half-life of paroxetine was 11.1 ± 5.2 (SD) hours. The average clearance was 88.7 ± 66.4 mL/min/kg. The mean area under the plasma drug concentration curve was 0.09 ± 0.10 μg/mL·hr. Within-subject variability of plasma paroxetine concentrations was generally not significant. Clearance and fractional urinary excretion of paroxetine were found to correlate with CYP2D6 activity. Two subjects developed hypomania necessitating drug discontinuation. No clinically significant changes in any safety assessments were noted. Conclusions: Paroxetine is more rapidly cleared in youths than adults and may be given once daily in this population. Short-term treatment with paroxetine appears safe and well tolerated in this relatively small sample of pediatric patients.",
keywords = "Depression, Paroxetine, Pharmacokinetics",
author = "Findling, {Robert L} and Reed, {Michael D.} and Carolyn Myers and O'Riordan, {Mary Ann} and Sandra Fiala and Lisa Branicky and Byron Waldorf and Blumer, {Jeffrey L.}",
year = "1999",
language = "English (US)",
volume = "38",
pages = "952--959",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Paroxetine pharmacokinetics in depressed children and adolescents

AU - Findling, Robert L

AU - Reed, Michael D.

AU - Myers, Carolyn

AU - O'Riordan, Mary Ann

AU - Fiala, Sandra

AU - Branicky, Lisa

AU - Waldorf, Byron

AU - Blumer, Jeffrey L.

PY - 1999

Y1 - 1999

N2 - Objective: To describe the pharmacokinetics and safety of paroxetine in children and adolescents and to explore the role of genetic polymorphisms in paroxetine pharmacokinetics. Method: Thirty depressed youths were enrolled. Samples for phenotyping with respect to cytochrome P450 2D6 (CYP2D6) and catechol-O-methyltransferase were collected. A single 10-mg dose of paroxetine was then administered followed by 5 days of blood and urine collection for pharmacokinetic analyses. Subjects subsequently received open treatment for 8 weeks, and weekly blood samples were obtained for plasma concentration measurements. Results: There was tremendous interindividual variability in paroxetine disposition. The mean half-life of paroxetine was 11.1 ± 5.2 (SD) hours. The average clearance was 88.7 ± 66.4 mL/min/kg. The mean area under the plasma drug concentration curve was 0.09 ± 0.10 μg/mL·hr. Within-subject variability of plasma paroxetine concentrations was generally not significant. Clearance and fractional urinary excretion of paroxetine were found to correlate with CYP2D6 activity. Two subjects developed hypomania necessitating drug discontinuation. No clinically significant changes in any safety assessments were noted. Conclusions: Paroxetine is more rapidly cleared in youths than adults and may be given once daily in this population. Short-term treatment with paroxetine appears safe and well tolerated in this relatively small sample of pediatric patients.

AB - Objective: To describe the pharmacokinetics and safety of paroxetine in children and adolescents and to explore the role of genetic polymorphisms in paroxetine pharmacokinetics. Method: Thirty depressed youths were enrolled. Samples for phenotyping with respect to cytochrome P450 2D6 (CYP2D6) and catechol-O-methyltransferase were collected. A single 10-mg dose of paroxetine was then administered followed by 5 days of blood and urine collection for pharmacokinetic analyses. Subjects subsequently received open treatment for 8 weeks, and weekly blood samples were obtained for plasma concentration measurements. Results: There was tremendous interindividual variability in paroxetine disposition. The mean half-life of paroxetine was 11.1 ± 5.2 (SD) hours. The average clearance was 88.7 ± 66.4 mL/min/kg. The mean area under the plasma drug concentration curve was 0.09 ± 0.10 μg/mL·hr. Within-subject variability of plasma paroxetine concentrations was generally not significant. Clearance and fractional urinary excretion of paroxetine were found to correlate with CYP2D6 activity. Two subjects developed hypomania necessitating drug discontinuation. No clinically significant changes in any safety assessments were noted. Conclusions: Paroxetine is more rapidly cleared in youths than adults and may be given once daily in this population. Short-term treatment with paroxetine appears safe and well tolerated in this relatively small sample of pediatric patients.

KW - Depression

KW - Paroxetine

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0032801746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032801746&partnerID=8YFLogxK

M3 - Article

C2 - 10434486

AN - SCOPUS:0032801746

VL - 38

SP - 952

EP - 959

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 8

ER -